1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small businesses. Confirm the full requirements in the official notice before applying.
Applications for Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44 Clinical Trial Not Allowed) are due January 7, 2028. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44 Clinical Trial Not Allowed) is funded by National Cancer Institute (NCI), NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs) is sponsored by Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) and Neuroendocrine Tumor Research Foundation (NETRF). This grant supports early-career basic or clinical scientists to conduct novel and innovative research in nuclear medicine related to neuroendocrine tumors, with the aim of generating preliminary data for further funding.
Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs) is sponsored by The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) / Neuroendocrine Tumor Research Foundation (NETRF). This grant supports basic or clinical scientists in the early stages of their careers to conduct novel and innovative research in neuroendocrine tumors using nuclear medicine. The goal is to generate preliminary data for future funding.
Advancing the European bio-based innovation enabled by biotechnology and biomanufacturing concepts is sponsored by European Commission — Horizon Europe. Expected Outcome: Project results are expected to contribute to all of the following expected outcomes: significant advance in the development of innovation in biotechnology, life sciences and/or biomanufacturing concepts, preparing future deployment of bio-based and bio-inspired processes, products and materials, as a basis for sustainable, fair, safe and circular value chains, contributing to decarbonisation, industrial competitiveness and the strategic autonomy of the EU and Associated Countries; improved environmental sustainability of the developed innovative bio-based solutions, with positive and quantifiable impact on climate and biodiversity, and circularity of the European bioeconomy via enhanced resource efficiency, including of biological feedstocks, water and energy, integrating bio-based sector to minimize and remediate waste production. Scope: Actions funded under this topic are relevant to the EU policies related to the European Commission communication on ‘Building the future with nature: Boosting Biotechnology and Biomanufacturing in the EU’, the Life Sciences Strategy, the upcoming EU Biotech Act, and Circular Economy Act, the EU strategy on research and technology infrastructure, the Clean Industrial Deal and the policies related to the digital transition (e.g. AI Act, etc.). It also contributes to the Start-ups and Scale-ups Strategy. Proposals should address the following activities: identify, select and develop further promising selected key technologies underpinning the bio-based innovation/industry, in particular R&D on synthetic/molecular biology, gene editing, metabolic engineering, microbiome [1] , and/or biofoundry approaches, covering all applications aiming at clean growth and environmental solutions. Advancing towards validation at a pilot-scale is encouraged, to enable future exploitation. The applications in health biotechnology, as well as the biofuel/bioenergy area are excluded, to avoid overlaps with Horizon Europe Clusters 1 and 5, respectively; ensure the integration of digital technologies (e.g. AI/Machine Learning, bioinformatics); advance the convergence of biotech and life sciences developed under the first point with Nature-based Solutions, e.g. for environmental applications, carbon sequestration [2] , biodiversity protection/enhancement, aligned with (bio-)circular economy principles (e.g. cascading biomass use), ensuring the environmental fate and sustainability is considered quantitatively at the earliest stage and ensuring safety to human health and environment is addressed and guaranteed; develop recommendations for policy makers and industrial actors, taking into account the available scientifically sound assessment of risks and benefits of the developed solutions. Proposals should involve SMEs – both as project beneficiaries and as external actors – and offer opportunities to newcomers (to Horizon Europe Cluster 6). Proposals should also engage with the civil society stakeholders such as NGOs and consumer organisations to seek stakeholder involvement and acceptance, thus advancing scale-up and facilitating future market uptake. Proposals need to ensure compliance with the ‘Do no significant harm’ (DNSH) principle. Proposals are encouraged to consider, where relevant, the data, expertise and services offered by European research infrastructures [3] , such as EMSO ERIC, EU-OPENSCREEN, ELIXIR, EMBRC ERIC, IBISBA. Efforts should be made to ensure that the data produced in the context of this topic is FAIR (Findable, Accessible, Interoperable and Re-usable). Cooperation with the parallel projects funded under topic HORIZON-CL6-2026-01-CIRCBIO-10: Bio-based innovation in society: supporting the sustainable way of living is encouraged, to benefit from synergies and avoid overlaps. Similarly, activities should benefit from synergies and avoid overlaps with ongoing projects, e.g. funded under the topic HORIZON-CL6-2022-CIRCBIO-02-05-two-stage: Life sciences and their convergence wi Programme areas: Horizon Europe (HORIZON), Global Challenges and European Industrial Competitiveness, Food, Bioeconomy Natural Resources, Agriculture and Environment, Bio-based Innovation Systems in the EU Bioeconomy Keywords: Agricultural biotechnology, Bio-based products (products that are manufactured using biological material as feedstock) bio-based materials, bio-based plastics, biofuels, bio-based and bio-derived bulk and fine chemicals, bio-based and bio-derived novel materials, Biochemistry and molecular biology, Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation, Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials, Cell biology and molecular transport mechanisms, Cell biology, Microbiology, DNA synthesis, modification, repair, recombination, degradation, Environmental biotechnology, Environmental biotechnology related ethics, Environmental biotechnology, bioremediation, biodegradation, General biochemistry and metabolism, Industrial biotechnology, Natural resources exploration and exploitation, Other biological topics, Plant sciences, botany, Proteomics, RNA synthesis, processing, modification and degradation, Social innovation, Social sciences, interdisciplinary, bio-based, bio-product, bioeconomy, biofoundry, bioinformatics, biomanufacturing, bioproduct, biotechnology, environmental biotechnology, gene editing, industrial biotechnology, life sciences, microbiome, synthetic biology
PAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read article